130 related articles for article (PubMed ID: 23999047)
1. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
[TBL] [Abstract][Full Text] [Related]
2. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
[TBL] [Abstract][Full Text] [Related]
3. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
5. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
[TBL] [Abstract][Full Text] [Related]
6. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
[TBL] [Abstract][Full Text] [Related]
8. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
9. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
11. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
[TBL] [Abstract][Full Text] [Related]
14. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
15. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
[TBL] [Abstract][Full Text] [Related]
16. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
17. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors.
Yan Q; Ding N; Li Y
Carbohydr Res; 2016 Feb; 421():1-8. PubMed ID: 26735747
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]